← Search & browse all drugs
GENITO URINARY SYSTEM AND SEX HORMONES › OTHER GYNECOLOGICALS › OTHER GYNECOLOGICALS › Prolactine inhibitors
quinagolide
G02CB04
Forms & Strengths
- Oral tablets: 25 mcg, 50 mcg, 75 mcg, 150 mcg titration pack
Adult Dosing
- Initial: 25 mcg once daily at bedtime for 3 days
- Titration: Increase by 25-50 mcg increments every 3 days
- Maintenance: Typically 75 mcg to 150 mcg once daily
- Administer with food to reduce gastrointestinal side effects
Pediatric Dosing
- Safety and efficacy not established in children or adolescents under 18 years
Indications
- Treatment of hyperprolactinemia (idiopathic or associated with pituitary micro- or macroadenomas)
- Management of prolactin-dependent menstrual disorders (amenorrhea, oligomenorrhea, menorrhagia) and galactorrhea
Mechanism of Action
- Selective dopamine D2 receptor agonist on anterior pituitary lactotroph cells
- Inhibits synthesis and secretion of prolactin
Contraindications
- Hypersensitivity to quinagolide or any excipient
- Severe hepatic impairment
- Severe renal impairment
Adverse Reactions
- Common: Nausea, vomiting, dizziness, headache, fatigue, abdominal pain
- Less common: Orthostatic hypotension, sleep disturbances, somnolence, nasal congestion, peripheral edema
- Rare: Psychotic disorders, sudden onset of sleep
Drug Interactions
- Dopamine antagonists (e.g., antipsychotics, metoclopramide): May antagonize the prolactin-lowering effect of quinagolide
- Antihypertensive agents: May potentiate blood pressure-lowering effects, increasing risk of orthostatic hypotension
- Alcohol: May impair tolerance and increase adverse neurological effects
Curated Content: Needs Vetting Before Put to Clinical Use